| abstract |
The present invention discloses the use of high affinity adenosine A 3 receptor antagonists for enhancing chemotherapeutic treatment of cancers expressing adenosine A 3 receptors and cancers expressing P-glycoprotein or MRP. In preferred embodiments, adenosine A 3 receptor antagonists are administered before or during administration of a taxane family, vinca alkaloid, camptothecin or antibiotic chemotherapeutic agent. |